Real world evidence of PD-L1, TMB prevalence and efficacy of 1st line chemotherapy in these high or low population for stage IV urothelial cancer

Trial Identifier: D419BR00014
Sponsor: AstraZeneca
NCTID:: NCT04052113
Start Date: October 2019
Primary Completion Date: March 2020
Study Completion Date: March 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations